Articles & Analysis
Week of 2026-W08
The Business Post Weekly Intelligence Briefing
Week of 19–25 February 2026: Deals, Distress & the Data Behind the Headlines
Source: ARTICLES | Period: 2026-02-19 to 2026-02-25
Stripe Eyes PayPal, Revolut Targets $100bn, and Ireland's Pharma Sector Braces for Trump's Next Move
A week that began with a US Supreme Court ruling against Trump's tariffs ended with Ireland's biggest companies recalculating their exposure — and two of the world's most valuable Irish-founded fintechs making headlines for very different reasons. Stripe's reported pursuit of PayPal would create a payments colossus; Revolut's fresh share sale at $100bn signals Europe's neobank era is entering a new phase. Meanwhile, the Supreme Court's tariff ruling — far from providing relief — may have accelerated the timeline for pharmaceutical-specific levies that would hit Ireland's most valuable export sector. Over the past seven days, 211 articles were published across Business Post's coverage, spanning fintech, pharma, aviation, property, and the courts.
By the Numbers
| Metric | Value | Signal |
|---|---|---|
| Stripe payments processed (2025) | $1.9 trillion | +34% YoY |
| Revolut Ireland customers | 3 million+ | Growing |
| Diageo dividend cut | 103.5c → 50c min | −52% |
| Flutter share price decline (2026 YTD) | −47% | Distress |
| Bank of America Flutter stake sold | €2.5bn | Major Exit |
| Interpath Ireland revenue growth | €13.1m → €19.6m | +50% |
| Irish CRE investment 2025 | €2.4bn | Stable |
| Dublin residential avg price (Feb 2026) | €574k | Elevated |
The Investigation: Ireland's Week in Business
Over the past seven days, a pattern emerged across Business Post's 211 articles: Ireland's most valuable sectors — pharma, fintech, data infrastructure, and aviation — are all simultaneously navigating external shocks while reporting strong underlying performance. The divergence between headline risk and operational reality is the story of this week.
Top Stories by Theme
| Story | Theme | Key Figure | Signal |
|---|---|---|---|
| Stripe explores PayPal acquisition | M&A & Deals | $159bn valuation | Transformative |
| Revolut eyes $100bn share sale | Fintech / IPO | £4.1bn revenue (2025) | Pre-IPO |
| Echelon Data Centres €1.7bn deal | Infrastructure | Morgan Stanley financing | Landmark |
| Irish pharma in US crosshairs | Legal / Regulatory | Section 232 risk | High Risk |
| Uniphar €200m EBITDA target | Pharma / Growth | CEO Ger Rabbette | On Track |
| Bank of America exits Flutter | Markets / Distress | €2.5bn stake sold | Bearish |
| Aer Lingus strategy analysis | Aviation | Lynne Embleton, CEO | Watch |
| Irish CRE investment +30% forecast | Property | Knight Frank | Bullish |
| Interpath Ireland revenue +50% | Insolvency / Advisory | Kieran Wallace | Structural |
| Primeline High Court landlord row | Legal | €6.7m damages claim | Litigation |
Sector Breakdown: Where Business Post Focused This Week
Financial Performance: Key Companies in the News
| Company | Key Metric | Value | Context |
|---|---|---|---|
| Revolut Ltd | Annual Revenue (2025 est.) | £4.1bn | Targeting $100bn+ valuation in H2 2026 share sale |
| Stripe (Dublin subsidiary) | Turnover (2024) | $5.1bn | +$1.3bn YoY; exploring PayPal acquisition |
| Uniphar PLC | EBITDA Target (2028) | €200m | Pharma division driving growth; new 330k sq ft Dublin hub |
| Diageo | Net Sales Change | −4% | Dividend slashed 52%; CEO Dave Lewis plans price cuts |
| Flutter Entertainment | Share Price (2026 YTD) | −47% | Bank of America exits €2.5bn stake |
| Kingspan | Revenue Growth (2025) | +7% | Advnsys data centre unit +12% revenue, +17% profit |
| Interpath Ireland | Revenue (2025) | €19.6m | +50% YoY; losses narrowed to €1m; Bridgepoint acquisition |
| Noel Kelly Management | Dividends Received (2025) | €1.5m | €1m from NK Management + €550k from CMS marketing |
The Connections: What the Data Reveals Beyond the Headlines
Articles are the starting point. Official records — CRO filings, court judgments, property registers — are what make the picture complete. This week, cross-referencing Business Post's coverage against official databases reveals connections that deepen, complicate, and occasionally contradict the public narrative.
The Radar: Three Signals Worth Watching
The Deep Dive: Two Companies Worth Watching Closely
This week's coverage surfaced two companies that deserve deeper investigation: Uniphar PLC, Ireland's publicly listed pharma and medtech distributor targeting €200m EBITDA by 2028, and the story of Noel Kelly's talent agency empire, which quietly extracted €1.5 million in dividends from its subsidiaries in 2025. Two very different businesses, two very different stories about how Irish companies generate and distribute value.
Uniphar PLC — The Pharma Distributor Quietly Building a European Empire
Uniphar Public Limited Company (CRO 224324) was incorporated in November 1994 and is headquartered at 4045 Kingswood Road, Citywest Business Park, Dublin. It operates three divisions: pharma (specialty and unlicensed medicines), medtech (European medical device distribution), and supply chain/retail (482 pharmacies). CEO Ger Rabbette has set a target of €200m EBITDA by 2028, driven primarily by the pharma division. The company recently invested in a 330,000 sq ft distribution centre in Dublin.
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| EBITDA Target (2028) | €200m | — | Target Set |
| Pharma Division Revenue Growth | High | Moderate | Accelerating |
| Medtech Division | High margin | High margin | Stable |
| Retail Pharmacies | 482 | ~480 | Stable |
| New Distribution Centre | 330,000 sq ft | — | Completed |
| CRO Share Capital (authorised) | €37.5m | €37.5m | Unchanged |
The question for 2026 accounts: Has Uniphar's pharma division maintained its growth trajectory despite tariff uncertainty, and has the new Dublin distribution centre delivered the cost transformation management promised?
Noel Kelly Management — Ireland's Talent Economy in Numbers
Noel Kelly's holding company, Noel Kelly Management (Holdings), received €1.5 million in dividends in 2025 from two subsidiaries: Cleary Consultancy Limited (the vehicle behind NK Management talent agency, €1m dividend) and Century Merchandising Services Limited (CMS marketing, €550k dividend). NK Management represents Pat Kenny, Baz Ashmawy, Ivan Yates, Matt Cooper, Caitríona Perry, and Doireann Garrihy. CMS recorded profits of €428,000 in 2025, up from €339,000.
| Entity | 2025 Profit | Dividend Paid | Retained Earnings |
|---|---|---|---|
| Cleary Consultancy (NK Management) | €92,000 | €1,000,000 | From reserves |
| Century Merchandising (CMS) | €428,000 | €550,000 | €1.2m remaining |
| Noel Kelly Management (Holdings) | — | €1,550,000 received | Holding company |
The question for 2026: Can NK Management rebuild its retained earnings base after the €1m dividend drawdown, and will CMS's marketing revenues hold up in a tighter advertising market?
Key People This Period
| Name | Role | Notable Activity | Connections |
|---|---|---|---|
| Ger Rabbette | CEO, Uniphar PLC | Targeting €200m EBITDA by 2028; pharma division as primary growth engine | Uniphar PLC |
| John Collison | President, Stripe | Stripe exploring PayPal acquisition; $159bn valuation; dismisses SaaS-pocalypse | Stripe/PayPal story |
| Gene Murtagh | CEO, Kingspan | Advnsys data centre unit +12% revenue, +17% profit; bullish on AI infrastructure | Kingspan Advnsys |
| Kieran Wallace | Head of Ireland, Interpath | Led 50% revenue growth to €19.6m; firm being acquired by Bridgepoint for £800m | Interpath Ireland |
| Dave Lewis | CEO, Diageo | Dividend cut from 103.5c to 50c minimum; net sales -4%; 'price repositioning' planned | Diageo results |
| Lynne Embleton | CEO, Aer Lingus | Needs to return to transatlantic strategy; Dublin Airport passenger cap threatens growth | Aer Lingus analysis |
| Eddie Byrne | CEO, Ires Reit | Welcomes new rental sector competition; new rental regulations from March 1 | Ires Reit |
| Noel Kelly | Founder, NK Management | €1.5m dividend from talent agency and marketing businesses in 2025 | NK Management |
One to Watch: Resurrect Bio
Resurrect Bio
| Metric | Value |
|---|---|
| Series A Funding (initial close) | $8.1m (€6.9m) |
| Lead Investor | Corteva Agriscience (Dow/DuPont spin-off) |
| Founded | 2021 |
| Technology | Targeted gene editing to resurrect native crop resistance genes |
| Market Opportunity | Plant pathogens cost farmers ~$300bn annually |
What they do: Resurrect Bio uses targeted gene editing to reactivate native resistance genes in crops, making them disease-resistant without chemicals. Co-founded by Cian Duggan (CEO, Trinity College Dublin background), Tolga Bozkurt, and Sophien Kamoun from the Sainsbury Laboratory.
Why it matters: This is not a Dublin tech startup — it is an Irish-co-founded deep science company working on one of the most pressing problems in global food security. The $8.1m Series A, led by Corteva Agriscience (the agricultural spin-off of Dow and DuPont), is a validation from one of the world's largest agri-chemical companies that gene editing is the future of crop protection. Ireland rarely produces deep biotech companies at this level. Resurrect Bio is one to watch over the next 3-5 years.
The number that matters: $300 billion — the annual cost to farmers of plant pathogens and pests. Even a 1% reduction in that cost is a $3 billion market. Resurrect Bio is targeting the entire value chain.
The Broader Picture: Courts, Property & The Week Ahead
The Irish Courts
The week of 19–25 February 2026 produced six High Court judgments, with two of direct relevance to the business community. The most significant for Irish business readers is the bankruptcy case of Re: Phelan, a reminder that personal insolvency proceedings continue to flow through the courts. The Pisarski v Kepak Cork case — involving a major Irish meat processor — is a workplace dispute with potential implications for employment law. Meanwhile, the Primeline logistics dispute, reported by Business Post this week, has a prior High Court history: Primeline VNE Ltd previously litigated against Centz Retail Holdings in 2022 over unpaid invoices.
| Citation | Parties | Subject | Why It Matters |
|---|---|---|---|
| [2026] IEHC 100 | Re: Phelan [A Bankrupt] | Personal bankruptcy | Ongoing personal insolvency pipeline; Kennedy J. |
| [2026] IEHC 94 | Pisarski v Kepak Cork Unlimited Company | Employment / workplace | Kepak is a major Irish meat processor; employment law implications |
| [2022] IEHC 365 | Primeline VNE Ltd v Centz Retail Holdings | Commercial dispute / invoices | Prior litigation history for Primeline, now in new €6.7m High Court dispute |
| High Court (Commercial List) | Primeline v Green Urban Logistics Airways | Landlord/tenant; €6.7m damages | Fast-tracked; Musgrave, GE Medical among affected customers |
| High Court | Denis O'Brien v DPC / Red Flag | GDPR / data access | O'Brien ordered to pay legal costs after appeal fails on all grounds |
Property Markets & Plans
The Irish commercial real estate market is entering a new cycle. Knight Frank's forecast of a 30% rise in CRE investment in 2026 — from €2.4 billion in 2025 — is backed by improving fundamentals: rate cuts, regulatory changes, and renewed institutional appetite. The residential market in Dublin recorded 572 transactions in February 2026, with an average price of €574,000 and a median of €463,000 — elevated but stable. The industrial and logistics sector is expected to grow from 10% to 20-25% of total CRE investment in 2026, driven by data centre and e-commerce demand.
| Sector | 2025 Share | 2026 Forecast | Key Driver |
|---|---|---|---|
| Retail | 28% | Stable | Large transactions >€100m; US investors active |
| Offices | 28% | Stable | Prime assets; Kennedy Wilson, Corum active |
| Living (BTR/co-living) | 24% | Growing | Rental regulation reset; Greystar, Ardstone active |
| Industrial & Logistics | 10% | 20–25% | Data centres; e-commerce; Echelon expansion |
The Week Ahead
The defining theme of the week of 19–25 February 2026 was the collision between Ireland's exceptional corporate performance and the external shocks threatening to disrupt it. Stripe is worth $159 billion and exploring the acquisition of PayPal. Revolut is targeting $100 billion. Echelon has secured €1.7 billion in infrastructure financing. Uniphar is on track for €200m EBITDA. And yet: the Supreme Court tariff ruling has opened a new front for pharmaceutical risk, Flutter is in freefall, Diageo has slashed its dividend, and the Central Bank Governor race is about to begin. Ireland's corporate sector has rarely been stronger — or more exposed to forces beyond its control.
What to Watch:
- Flutter's Q4 results release — the first major test of whether the 47% share price decline reflects fundamental deterioration or market overreaction.
- US Section 232 pharmaceutical investigation timeline — any announcement of tariff rates on pharma imports would be a material event for Ireland's economy.
- Revolut's share sale process — watch for investor documentation and valuation anchoring in H2 2026.
- Central Bank Governor appointment — expected Q2 2026; the choice will signal Ireland's regulatory philosophy for the next decade.
- Stripe/PayPal deal progress — any regulatory filing or formal announcement would be the biggest Irish corporate story in years.